– Backgrounder –
Servier is France’s leading independent pharmaceutical company and the country’s second largest drug
company. Servier is present in 140 countries worldwide. R&D at Servier spans a range of therapeutic
fields, with the main areas of focus being cardiovascular disease, neuroscience, oncology, metabolic
disorders, and rheumatology. In the field of cardiovascular disease in particular, Servier is one of the
principal research organizations dedicated to the development of new medicines.
Servier has a long-standing interest in the field of cardiovascular disease. Nearly two thirds (63%) of
Servier’s global turnover from medicines is made up of drugs targeted at cardiovascular diseases.
Servier is unique among global pharmaceutical companies in that all the company’s cardiovascular
products it has introduced have stemmed from its own research efforts.
is the first and only specific and selective I
f current inhibitor of the sinus node.
Procoralan was approved in 2005 by the European regulatory authorities (EMEA) for clinical use in
selected patients with chronic stable angina. It is currently available in around 70 countries worldwide.
Servier’s cardiovascular portfolio also includes Coversyl® (perindopril),
Servier’s leading product for
high blood pressure, heart failure, and for the treatment of patients with stable coronary artery disease
(CAD) to reduce the risk of coronary events, Vastarel MR® (trimetazidine)
for stable angina and
Preterax® (perindopril / indapamide)
and Natrilix® SR (indapamide)
Servier and landmark clinical trials
Servier has been involved in several large-scale outcomes clinical trials for several years including the
ion of the If
Inhibitor ivabradine in patients with coronary
disease and left ventricUL
ar dysfunction) trial, which demonstrated the benefits of Procoralan
(ivabradine) in reducing cardiovascular events in patients with coronary artery disease (CAD) receiving
current preventative therapy . The results of this trial have major implications for the management of
Other Servier trials include the ADVANCE
ction in D
iabetes and V
valuation) study. This is the world’s largest prospective mortality/morbidity
trial in patients with type 2 diabetes to date. The study demonstrated the effects of blood pressure
lowering with Preterax®-based therapy1 and intensive glucose-lowering with Diamicron MR-based
therapy2 on the risk of complications in patients with type 2 diabetes.1
The efficacy of perindopril alone and in combination has been investigated in a number of trials.
tudy) showed that perindopril 4 mg +
indapamide 2.5 mg reduced the risk of stroke by 29% in patients with a history of cerebrovascular
uropean trial on R
f cardiac events with P
erindopril in stable coronary
rtery disease) showed that perindopril 8 mg is associated with a 20% reduction in the risk of
cardiovascular death, myocardial infarction, and cardiac arrest compared with placebo in patients with
Other significant, independent, investigator-led trials include ASCOT-BPLA
5 in hypertension (amlodipine
+ perindopril), PREAMI
6 in postmyocardial infarction in elderly (perindopril) and PEP-CHF
7 in diastolic
*Depending on the country, ivabradine is available as Procoralan®, Coralan®, Coraxan®, or Corlentor®
1. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular
and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet.
2007 ; 370 : 829-40.
2. ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N
Engl J Med
. 2008 ; 358 : 2560-72.
3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105
individuals with previous stroke or transient ischaemic attack. Lancet
2001 ; 358 : 1033-41.
4. Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators.
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease:
randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet.
2003 ; 362 : 762-68.
5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine
adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac
Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet.
6. The PREAMI Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular
remodelling and clinical outcome. Results of the Randomized Perindopril and Remodeling in Elderly with Acute Myocardial
Infarction (PREAMI) study. Arch Intern Med.
2006 ; 166 : 659-66.
7. PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J.
EDUARD RODRÍGUEZ FARRÉ Y SALVADOR LÓPEZ ARNAL El poder del lado oscuro de la fuerza. Presiones, falacias e intereses atómico-nucleares Este artículo expone el marco –político, económico, militar, de seguridad, de(des)información a la ciudadanía– en el que se suele mover y proyectar laindustria nuclear. En oposición a argumentos publicitarios, pletóricos dedefensas interesadas,
Research Update on Challenging Behaviour – Summer 2008 The following is a necessarily subjective selection of recent reading in the field of challenging behaviour. It includes two major multi site studies, one evaluating the effect of psychotropic medication on challenging behaviour (4) and another evaluating the impact of person centred planning (9). Other themes in this selection inclu